Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that management will participate in a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 7:30 a.m. PT / 10:30 a.m. ET in New York City.

A live audio webcast of the event will be available in the Investors section of Pardes’ website at www.pardesbio.com, with an archived replay available for 30 days following the event.

About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are dedicated to discovering and developing potent and easy-to-prescribe oral antiviral drug candidates so that patients everywhere can get well sooner. For more information, please visit www.pardesbio.com.

Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes Biosciences’ press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.

Investor Contacts:
Patrick O’Brien
pobrien@pardesbio.com

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Staff

Recent Posts

CardioComm Solutions Provides Update Respecting Debt Settlement

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…

2 hours ago

CONMED Corporation to Announce Second Quarter 2024 Financial Results on July 31, 2024

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced it will report financial results for the…

3 hours ago

AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on…

3 hours ago

Youth Inventors Compete at The Henry Ford during RTX Invention Convention U.S. Nationals June 5-7, 2024, in Dearborn, Michigan

DEARBORN, Mich., July 8, 2024 /PRNewswire/ -- The Henry Ford hosted over 435 youth inventors…

3 hours ago

Leading Medical Claims Management provider, Medlogix, LLC Announces the Acquisition of ReviewWorks

HAMILTON, N.J., July 8, 2024 /PRNewswire/ -- Medlogix, LLC, a leading, national medical claims management…

3 hours ago

Gymdesk Announces a $32.5 Million Strategic Growth Investment from Five Elms Capital

KANSAS CITY, Mo., July 8, 2024 /PRNewswire/ -- Gymdesk, a leading provider of member management…

3 hours ago